Trials / Completed
CompletedNCT01171417
A Treatment With Fulvestrant and Exemestane in Postmenopausal Patients With Advanced Hormone Receptor-Positive (HR) + Breast Cancer
An Epidemiological Prospective Cohort Study to Describe Treatment Patterns of Fulvestrant And ExemeSTane in Postmenopausal Patients With Advanced HR+ Breast Cancer Under Real-life Conditions in GERmany
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 570 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
For patients receiving Faslodex 500 mg, to compare the effectiveness in terms of Time to Progression (TTP) as a function of the line of treatment (i.e. 1st vs. 2nd vs. 3rd line). For all patients, to collect and explore real-life data on the epidemiology and management of Pseudomyxoma Peritonea (PMP) patients with HR+ advanced breast cancer (ABC) treated with Faslodex 500 mg or exemestane.
Conditions
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2013-11-01
- Completion
- 2013-11-01
- First posted
- 2010-07-28
- Last updated
- 2014-02-27
Locations
92 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01171417. Inclusion in this directory is not an endorsement.